Press Releases
NanoHybrids Launches Revolutionary Contrast Agent to Measure EPR Effect at 2018 SPIE BiOS Expo
NanoHybrids announces the launch of PAtrace, a proprietary nanoparticle created to provide high resolution visualization and verification of the enhanced permeability and retention (EPR) effect in heterogeneous tumor models. The contrast agent is designed for use with photoacoustic (PA) imaging systems and produces depth-resolved 3D mapping of tumor permeability and retention without requiring significant preparation time...........Read more: html | pdf
NanoHybrids Awarded NIH Grant to Advance Nanoparticle Enabled Photodynamic Therapy for Oral Cancer
NanoHybrids Inc.has been awarded $300,000 by the National Cancer Institute of the National Institutes of Health (NIH) through the Small Business Technology Transfer (STTR) program to enhance the therapeutic efficacy of photodynamic therapy (PDT) in oral cancers.........Read more.
Targeted Hyperthermia Treatment Accepted for Full Characterization at the Frederick National Laboratory for Cancer Research
Siva Therapeutics (“Siva”) in conjunction with NanoHybrids Inc. is pleased to announce that its Targeted Hyperthermia™ technology has successfully passed through the first stages of nanoparticle characterization at the Frederick National Laboratory (FNL) for Cancer Research in Frederick, Md.........Read more.
NanoHybrids Launches 30 nm Gold NanoSpheres
NanoHybrids has announced that their signature NanoSphere product line will now include 30 nm Gold NanoSpheres. With this addition, NanoHybrids now offers standard spherical nanoparticles with 5 nm, 10 nm, 20 nm, 30 nm, 40 nm, and 60 nm diameters. "The 30 nm particles allow us to offer consistent, reliable, and quality products across a full spectrum of gold nanosphere sizes and research needs.........Read more.
NSF Funds NanoHybrids' Improved Chemotherapy Delivery Platform
Adding to their R&D pipeline, Nanohybrids, Inc. has received a Phase I Small Business Innovation Research (SBIR) grant from the NSF. The grant is to develop a nanocarrier platform to deliver hydrophobic cancer drugs. Poor solubility is a common and serious issue that severely complicates the process of bringing new drugs to market and delivering them to patients without toxicity. NanoHybrids now proposes to shift the paradigm of chemotherapeutic delivery using nanotechnology expertise........Read more.
NanoHybrids Receives Funding to Develop Breakthrough Technology in Cancer Detection and Diagnosis
NanoHybrids recently received $225,000 from the National Cancer Institute (NCI) to develop a new breakthrough immunohistochemistry (IHC) technology. The project builds on NanoHybrids expertise producing high quality gold nanoparticles that enable innovative approaches to imaging. With this Phase I Small Business Innovation Research (SBIR) grant, NanoHybrids will develop a new photoacoustic microscopy platform to quantitatively assess biomarker distribution in biopsied and histological human samples........Read more.
NanoHybrids Launches Gold Nanoparticles Custom Designed to Improve Lateral Flow Sensitivity and Reproducibility
NanoHybrids today announced the release of a new line of spherical gold nanoparticles designed to enable highly sensitive and reliable lateral flow immunoassays. Careful selection of indicator particles is absolutely critical to the performance of any lateral flow assay. NanoHybrids’ new line of monodisperse gold nanoparticles can enable the development of lateral flow assays that meet the highest specifications of the industry, particularly with respect to sensitivity and reproducibility........Read more.
NanoHybrids Enters into Distribution Agreement with Eikonix, UK
NanoHybrids has entered into an agreement that adds NanoHybrids’ premium gold nanoparticles to Eikonix's extensive offering of scientific research products and services.
“Since our launch last year, NanoHybrids products have been quickly gaining popularity with imaging researchers thanks to our high quality and personalized customer service,” said Nishi Viswanathan, Director, Product Development & Marketing at NanoHybrids. “We are very pleased to partner with Eikonix, and believe that this agreement will reinforce NanoHybrids’ position as a worldwide supplier of high quality gold nanoparticles and contrast agents........Read more.
NanoHybrids Publishes White Paper on ‘Make Vs Buy’ Gold Nanoparticles
The paper takes an in-depth look at various costs involved in making gold nanoparticles by dividing the process into two main phases - the research phase that involves fine-tuning protocols and characterization and the actual production phase. A break-even analysis is conducted to compare the costs of making nanoparticles with the cost associated with buying them……Read more.
Nanohybrids Receives SBIR Funding to Develop Molecular Imaging Agent for Atherosclerosis
Rupture of atherosclerotic plaques account for around 70% of fatal acute myocardial infarctions and/or sudden coronary deaths. Plaques that are vulnerable to rupture have certain specific features, which can be detected by various intravascular imaging techniques. However, currently available techniques are limited in their ability to target and image macrophage activity, a crucial component of atherosclerotic plaque characterization. NanoHybrids is developing a contrast agent for intravascular imaging……Read more.
Nanohybrids Launches an Exclusive Line of Gold Nanoparticles
“Frustrated by inconsistent imaging results due to highly variable shape, size and other properties of commercially available gold nanoparticles, our team has developed highly monodisperse gold nanorods and nanospheres that will help scientists obtain consistent and better quality data. We also have a policy of ‘no proprietary coatings’ which means that unlike some companies in this space, we offer full transparency on surface chemistry, making it easier for our customers to modify and use these particles depending on their application,” says Co-founder and Chief Technology Officer……Read more.